Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.

CONCLUSION: Overexpression and abrogated zonation of PDE-5 likely contribute to the pathogenesis of cirrhotic portal hypertension. PDE-5 inhibition may therefore be a reasonable therapeutic approach for portal hypertension. PMID: 30344420 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30344420?dopt=Abstract

Source: World Journal of Gastroenterology : WJG - October 14, 2018 Category: Gastroenterology Authors: Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W Tags: World J Gastroenterol Source Type: research